Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis

Back

ESC Premium Access

Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis

Session: Congress committee e-posters choice in heart failure

Topic: Pharmacotherapy

Speaker: Doctor G. Steiner-Gager (Vienna, AT)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

Add to my library

About the speaker

Doctor Gloria Steiner-Gager

Medical University of Vienna, Vienna (Austria)

0 follower

46 more presentations in this session

Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes

Speaker: Doctor A. Sharma (Montreal, CA)

Access

Abstract

Slides

SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis

Speaker: Doctor V. Razuk (New York, US)

Access

Abstract

Slides

Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin

Speaker: Doctor J. Kolwelter (Erlangen, DE)

Access

Abstract

Slides

Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial

Speaker: Doctor M. Senni (Bergamo, IT)

Access

Abstract

Slides

Empagliflozin reduces TNFa-induced reactive oxygen species through inhibition of the human endothelial Na+/H+ exchanger 1

Speaker: Doctor L. Uthman (Nijmegen, NL)

Access

Abstract

Slides

Access the full session

Congress committee e-posters choice in heart failure

Speakers: Doctor G. Steiner-Gager, Doctor A. Sharma, Doctor V. Razuk, Doctor J. Kolwelter, Doctor M. Senni...

Access

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources